^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
anti-Claudin 18.2 CAR-T cell therapy
i
Other names: anti-Claudin 18.2 CAR-T cell therapy, LCAR-C182A/LCAR-C182B/LCAR-C182C cells, LB1904, LCAR-C182
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
First Affiliated Hospital Xi'an Jiaotong University, Legend Biotech
Drug class:
CLDN18.2-targeted CAR-T immunotherapy
Related drugs:
over4years
A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
P1, N=2, Terminated, First Affiliated Hospital Xi'an Jiaotong University | N=18 --> 2 | Trial completion date: Dec 2023 --> Mar 2020 | Recruiting --> Terminated | Trial primary completion date: Mar 2023 --> Mar 2020; the Preliminary data, progress of this study and the adjustment of the pipeline and strategy .
Clinical • Enrollment change • Trial completion date • Trial termination • Trial primary completion date • CAR T-Cell Therapy • IO biomarker
|
CLDN18 (Claudin 18) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL8 (Chemokine (C-X-C motif) ligand 8) • IL2 (Interleukin 2)
|
anti-Claudin 18.2 CAR-T cell therapy
Share via
